The Phenylketonuria Treatment Market is Expected to Grow Significantly Due to the Launch of Emerging Therapies During the Forecast Period (2021-30)

The Phenylketonuria Treatment Market is Expected to Grow Significantly Due to the Launch of Emerging Therapies During the Forecast Period (2021-30)

“Phenylketonuria Market”
The launch of therapies such as SYNB1618 and others are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM.

DelveInsight’s Phenylketonuria market report provides thorough comprehension of Phenylketonuria, historical and forecasted epidemiology, and Phenylketonuria market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).

Some of the Key Highlights from the Phenylketonuria Market Report

  • According to DelveInsight’s Phenylketonuria epidemiology insights, the total diagnosed prevalent cases was found to be 49,887 in the 7MM in 2020.

  • Among the EU5 countries, Germany has the highest number of Phenylketonuria cases while Spain has the least number of cases in 2020.

  • According to the National PKU Alliance, there are currently more than 16,000 people in the United States who have PKU.

  • Key companies across the globe such as Synlogic, Censa Pharmaceuticals, Homology Medicines, Biomarin Pharmaceuticals, and others are diligently working toward the development of novel treatment therapies and devices for Phenylketonuria treatment.

  • Synlogic’s SYNB-618 was granted orphan drug designation by the US FDA in 2017 for the Phenylketonuria treatment, and it was also granted Fast track designation by the US FDA in 2018.

  • Homology Medicines is developing HMI-102, a gene therapy, for the treatment of adult patients with PKU.

Have queries? Request for the sample to get the answers for all your queries @ Phenylketonuria Treatment Options

The Phenylketonuria (PKU) market report also covers current treatment practices, emerging drugs, Phenylketonuria (PKU) market share of individual therapies, and current and forecasted Phenylketonuria (PKU) market Size from 2018 to 2030, segmented by seven major markets.

Phenylketonuria: Overview

Phenylketonuria (PKU) is an inborn metabolic error that can be detected during the first days of life through routine newborn screening. PKU is defined by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), which is responsible for the amino acid phenylalanine processing.

Phenylketonuria Epidemiology Segmentation

The Phenylketonuria report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into: 

  • Phenylketonuria Diagnosed Prevalent Cases 

  • Phenylketonuria Age-Specific Diagnosed Prevalent Cases 

  • Phenylketonuria Severity-Specific Diagnosed Prevalent Cases 

  • Phenylketonuria Diagnosed Prevalent Cases by Mutation Type

Phenylketonuria Treatment Landscape

There is currently no cure for Phenylketonuria (PKU); however, the most common treatment is a dietary restriction of phenylalanine (Phe) to the minimum required for normal growth, supplemented with specially designed medical foods. As a result, dietary therapy is the first line of Phenylketonuria treatment. Apart from this, there are some FDA-approved drugs such as Kuvan (sapropterin dihydrochloride) and Palynziq (pegvaliase-pqpz) that are used for Phenylketonuria treatment.  

Phenylketonuria Market

The launch of therapies such as SYNB1618, CNSA-001, HMI-102, and others by key pharmaceutical companies such as Synlogic, Censa Pharmaceuticals, Homology Medicines, and several others are anticipated to provide a major push to the growth of the Phenylketonuria market size in the forecast period 2021-30 in the 7MM. 

Get a detailed analysis of the phenylketonuria therapeutics market @ Phenylketonuria Treatment Market

Phenylketonuria Pipeline Therapies and Key Companies 

  • SYNB1618: Synlogic

  • CNSA-001: Censa Pharmaceuticals

  • HMI-102: Homology Medicines

  • BMN 307: Biomarin Pharmaceuticals

Table of Contents 


Key insights


Executive Summary of Phenylketonuria


Phenylketonuria: Market Overview at a Glance


Disease Background and Overview: Phenylketonuria


Phenylketonuria Patient Journey


Case Reports


PhenylketonuriaEpidemiology and Patient Population


Phenylketonuria: Country-Wise Epidemiology


Phenylketonuria Treatment & Medical Practices


Phenylketonuria Marketed Products


Phenylketonuria Emerging Therapies


Phenylketonuria Pipeline Profiles


Phenylketonuria: Market Size


7MM Phenylketonuria: Country-Wise Market Analysis


Phenylketonuria Market Drivers


Phenylketonuria Market Barriers


SWOT Analysis


KOL Views


Phenylketonuria Reimbursement and market access




DelveInsight Capabilities




About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Hyperphosphatemia Market

Get comprehensive historical and forecast analysis of Hyperphosphatemia Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Akebia Therapeutics, Vifor Fresenius Medical Care Renal Pharma, Astellas Pharma, Ardelyx, Shield Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States